NIH-funded research R21 grant

Using modified stem cell particles to treat degenerative disc disease

Official title: Extracellular vesicles produced by CRISPR-activated MSCs: A potential therapy for degenerative disc disease

Funded at Rochester Institute of Technology · NIH-10873279 · Data updated 2026-11-12

This study is exploring a new treatment for low back pain caused by degenerative disc disease, using tiny particles from specially modified stem cells to help reduce inflammation and promote healing in your discs, which could lead to less pain and better movement.

Quick facts

Grant typeR21 grant
Study typeNIH-funded research
Funding institutionRochester Institute of Technology
NIH-funded
Lab location1 site (Rochester, United States)
Project startSeptember 1, 2023
Project endJuly 31, 2026
Funding year2024
Award (this year)$163,110
NIH project number5R21AR081987-02
Project IDNIH-10873279 on NIH RePORTER

Who could benefit from this research

Could help

Ideal candidates for this research are individuals experiencing chronic low back pain due to degenerative disc disease.

Less likely to help

Patients with acute back pain not related to degenerative disc disease may not benefit from this research.

What this research studies

This research investigates the use of extracellular vesicles (EVs) produced by genetically modified mesenchymal stem cells (MSCs) as a potential therapy for degenerative disc disease (DDD), a common cause of low back pain. The approach focuses on enhancing the regenerative properties of these EVs to combat inflammation and promote healing in the intervertebral discs. By modifying MSCs to increase the production of specific proteins, the study aims to improve the therapeutic effects of the EVs without the complications associated with direct cell therapies. Patients may benefit from a novel treatment option that could alleviate pain and improve mobility.

Why it matters

Potential benefit: If successful, this research could provide a new, less invasive treatment option for patients suffering from degenerative disc disease.

How similar studies have gone: While the use of extracellular vesicles in therapy is a relatively novel approach, preliminary studies have shown promise in similar applications.

Where this research is happening

  • Rochester Institute of Technology
    Rochester, United States
    Active

Researchers

  • Principal investigator: Wuertz-Kozak, Karin — Rochester Institute of Technology
  • Study coordinator: Wuertz-Kozak, Karin

Related research

Other NIH-funded projects on the same topics.

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.